Dianthus Therapeutics, Inc. (DNTH) vs Erasca, Inc. (ERAS)
A side-by-side comparison of Dianthus Therapeutics, Inc. and Erasca, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DNTH
Dianthus Therapeutics, Inc.
$84.49HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
ERAS
Erasca, Inc.
$14.11HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — DNTH vs ERAS
growth of $100 · dividends reinvested · last 5yDNTH -35.9% (-8.5%/yr)ERAS -15.5% (-3.3%/yr)ERAS compounded faster over this window
DNTH ERAS
DNTH vs ERAS: by the numbers
- •ERAS is the larger company ($4.90B vs $4.73B market cap).
- •Both run net losses; ERAS's is the smaller (0.00% vs -1570.85% net margin).
Metrics side by side
Valuation
| Metric | DNTH | ERAS |
|---|---|---|
| P/S ratio | 2482.09 | N/A |
| P/B ratio | 4.03 | 13.53 |
Profitability
| Metric | DNTH | ERAS |
|---|---|---|
| Gross margin | 96.01% | 0.00% |
| Operating margin | -8739.34% | 0.00% |
| Net margin | -1570.85% | 0.00% |
| ROE | -2.55% | -79.37% |
| ROIC | -18.48% | -38.03% |
Growth (annualized)
| Metric | DNTH | ERAS |
|---|---|---|
| Total return CAGR (5Y) | -5.50% | -8.34% |
Frequently asked
- How have DNTH and ERAS total returns compared?
- Over the past 5 years, DNTH delivered -5.50% and ERAS delivered -8.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.